Dinutuximab with Chemotherapy

Phase 2

United Therapeutics Corporation (UTHR)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Neuroblastoma

View Full Landscape

Drug Information

Target Indication

Neuroblastoma

Clinical Trial

NCT05421897

Last updated: 9/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/14/2015

Unituxin

Unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). It is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

UTHR

United Therapeutics Corporation

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

UT-15Phase 3

Pulmonary Hypertension

RalinepagPhase 3

Pulmonary Arterial Hypertension